Cargando…

WT1 peptide-based immunotherapy for refractory thymic epithelial malignancies

Detalles Bibliográficos
Autores principales:	Suzuki, Mikito, Hishida, Tomoyuki, Asakura, Keisuke, Asamura, Hisao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2019
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8794358/ https://www.ncbi.nlm.nih.gov/pubmed/35118240 http://dx.doi.org/10.21037/med.2019.04.01

Ejemplares similares

WT1 as an immunotherapy target for thymic epithelial tumors: a novel method to activate anti-tumor immunity
por: Takahashi, Nobuyuki, et al.
Publicado: (2019)

Four cases of completion lobectomy for locally relapsed lung cancer after segmentectomy
por: Suzuki, Shigeki, et al.
Publicado: (2021)

Survival comparison between thymic carcinoma and thymic carcinoid: does it matter in clinical practice?
por: Hishida, Tomoyuki
Publicado: (2019)

On the staging of thymic epithelial neoplasms
por: Suster, David, et al.
Publicado: (2019)

Double stapling method for closure of intraoperative alveolar air leakage adjacent to the staple line: a randomized experimental study on ex vivo porcine lungs
por: Suzuki, Takahiro, et al.
Publicado: (2022)

Feasibility and safety of percutaneous cryoablation under local anesthesia for the treatment of malignant lung tumors: a retrospective cohort study
por: Kaseda, Kaoru, et al.
Publicado: (2022)

Best practices and guidelines for the management of thymic epithelial tumors
por: Giaccone, Giuseppe, et al.
Publicado: (2019)

Separate evaluation of unilateral lung function using upright/supine CT in a patient with diaphragmatic paralysis()
por: Suzuki, Takahiro, et al.
Publicado: (2022)

The impact of radiomics in predicting oncologic behavior of thymic epithelial tumors
por: Ozawa, Yoshiyuki, et al.
Publicado: (2019)

Indolent stage IVA thymic malignancies managed with multimodality treatments
por: Hamaji, Masatsugu
Publicado: (2020)

Bridging over troubled waters: the doubling time and histological subtypes of thymic epithelial tumors
por: Kashima, Jumpei, et al.
Publicado: (2020)

Antitumor effect of oral cancer vaccine with Bifidobacterium delivering WT1 protein to gut immune system is superior to WT1 peptide vaccine
por: Shirakawa, Toshiro, et al.
Publicado: (2017)

Induction chemotherapy for locally advanced thymic epithelial tumors: consideration from the RYTHMIC prospective cohort
por: Nakagawa, Kazuo
Publicado: (2019)

An overview: ongoing systemic therapy trials in thymic epithelial tumors around the world-will anything “hit”?
por: Merveilleux du Vignaux, Claire, et al.
Publicado: (2021)

Medullary Thymic Epithelium: A Mosaic of Epithelial “Self”?
por: Farr, Andrew G., et al.
Publicado: (1998)

Narrative review of immunotherapy in thymic malignancies
por: Benitez, Jose Carlos, et al.
Publicado: (2021)

Prognostic factors affecting survival in patients with non-small cell lung cancer treated with salvage surgery after drug therapy: a multi-institutional retrospective study
por: Suzuki, Shigeki, et al.
Publicado: (2023)

Clinical TNM staging of thymic epithelial malignancies
por: Ackman, Jeanne B.
Publicado: (2019)

Long term efficacy of WT1 peptide vaccine in patients with WT1 overexpressing hematopoeitic and solid malignancies
por: Letsch, Anne, et al.
Publicado: (2013)

Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectives
por: Ao, Yong-Qiang, et al.
Publicado: (2023)

Wt1, the mesothelium and the origins and heterogeneity of visceral fat progenitors
por: Chau, You-Ying, et al.
Publicado: (2015)

Thymic epithelial tumors diagnosis and management: the importance of an international multidisciplinary approach
por: Molina, Thierry Jo
Publicado: (2019)

An appropriate choice for immunotherapy in malignant pleural mesothelioma
por: Fujimoto, Nobukazu
Publicado: (2020)

WT1 Peptide Cancer Vaccine for Patients with Hematopoietic Malignancies and Solid Cancers
por: Oka, Yoshihiro, et al.
Publicado: (2007)

Immunobiology of Thymic Epithelial Tumors: Implications for Immunotherapy with Immune Checkpoint Inhibitors
por: Tateo, Valentina, et al.
Publicado: (2020)

Immunotherapy for Management of Thymic Epithelial Tumors: A Double-Edged Sword
por: Ballman, Madison, et al.
Publicado: (2022)

Histological and prognostic data on surgically resected early-stage lung adenocarcinoma
por: Yotsukura, Masaya, et al.
Publicado: (2020)

Advancement in Diagnostic Imaging of Thymic Tumors
por: Gentili, Francesco, et al.
Publicado: (2021)

Determining extent of invasion and follow-up of thymic epithelial malignancies
por: Benveniste, Marcelo F., et al.
Publicado: (2019)

Cellular immunotherapy for refractory hematological malignancies
por: Reagan, John L, et al.
Publicado: (2013)

Treatment of malignant pleural effusions: the case for localized immunotherapy
por: Donnenberg, Albert D., et al.
Publicado: (2019)

Combined Ravitch and Nuss procedure for patients with severe pectus excavatum: technique and initial results
por: Masai, Kyohei, et al.
Publicado: (2023)

Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide
por: Oji, Yusuke, et al.
Publicado: (2016)

Phase 1/2 study of the WT1 peptide cancer vaccine WT4869 in patients with myelodysplastic syndrome
por: Ueda, Yasunori, et al.
Publicado: (2017)

The role of immunotherapy for management of advanced thymic epithelial tumors: a narrative review
por: Rajan, Arun, et al.
Publicado: (2021)

Immunotherapy and Targeted Therapies Efficacy in Thymic Epithelial Tumors: A Systematic Review
por: Agrafiotis, Apostolos C., et al.
Publicado: (2023)

The progressive fragmentation of the KIT/PDGFRA wild-type (WT) gastrointestinal stromal tumors (GIST)
por: Nannini, Margherita, et al.
Publicado: (2017)

WT1 Trio Peptide-Based Cancer Vaccine for Rare Cancers Expressing Shared Target WT1
por: Oji, Yusuke, et al.
Publicado: (2023)

AB002. Anlotinib as salvage treatment for patients with relapsed and refractory thymic epithelial tumors
por: Wang, Chang-Lu, et al.
Publicado: (2022)

WT1 peptide analogue WT1-126Y enhances leukemia lysis
por: Alqudaihi, Ghofran, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_kspgtc8mnggoot9rcq3brnq2c7